Perrigo Banks On Product Launches, OTC Switches For "Significant Growth"
This article was originally published in The Tan Sheet
Perrigo is "poised for some significant growth" with $180 million in new product sales expected in the firm's current fiscal year, according to President and CEO Joseph Papa.
You may also be interested in...
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.
OTC Allegra could soon face competition from private-label fexofenadine marketed by Perrigo, which acquired U.S. rights from ANDA-filer Teva.
Sanofi-Aventis will launch nonprescription Allegra allergy relief products March 4, but the line might not beat private-label fexofenadine products to store shelves.